Aptamer-Based Microvesicle Targeting for Cancer Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for cancer and other diseases involving microvesicles lack specificity and efficiency, particularly in targeting microvesicle surface antigens, which are indicative of cancer cells.
Innovation Solution
Development of aptamers that bind specifically to microvesicle surface antigens, including those shed from prostate and breast cancer cells, allowing for diagnostic, prognostic, and therapeutic applications by modulating signal transduction and enhancing delivery of active agents to disease sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic and therapeutic approaches are used to target microvesicle surface antigens, then treatment can be provided, but specificity and efficiency are insufficient
Solution Approach 1:
The patent changes the molecular parameters of the binding agent by using aptamers (nucleic acid molecules) instead of conventional antibodies or proteins. These aptamers are designed with specific sequence lengths (e.g., 10-50 nucleotides) and chemical structures that enable high-specificity binding to microvesicle surface antigens through non-Watson-Crick interactions, thereby resolving the contradiction between specificity and efficiency in conventional approaches
Solution Approach 2:
The patent creates simplified molecular copies of the binding function through aptamers that can be generated via in vitro selection from pools of random sequence oligonucleotides. This copying process allows rapid generation of leads with tightly controlled specificity and affinity, improving both measurement precision and productivity compared to conventional methods
2Reliability
If aptamers are used to bind microvesicle surface antigens, then specificity and affinity are improved, but the complexity of the selection and characterization process increases
Solution Approach 1:
The patent employs self-service principles through in vitro selection processes where aptamers are generated and selected automatically through biochemical interactions rather than requiring complex biological systems. The aptamers self-assemble and self-select based on their binding affinity to target microvesicle surface antigens, reducing the need for complex characterization procedures while maintaining high reliability
Solution Approach 2:
The patent simplifies the selection and characterization process by changing the fundamental parameters of the binding agent from proteins to nucleic acids. This parameter change enables more straightforward synthesis, selection, and characterization procedures while achieving superior specificity and reliability in targeting microvesicle surface antigens
3Reliability
If aptamers are administered to treat cancer, then therapeutic efficacy is improved, but the need for precise dosing and administration control increases
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the therapeutic agent by using small molecule aptamers (10-50 kDa) instead of large protein antibodies. This parameter change results in improved therapeutic efficacy through better tissue penetration and cellular uptake, while the small size and chemical stability of aptamers simplify dosing and administration control, making them easier to manage clinically
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Aptamers provide high specificity and affinity, enabling effective diagnosis, prognosis, and therapy by targeting microvesicle surface antigens, enhancing delivery of therapeutic agents and reducing microvesicle levels, thereby modulating biological activity and immune suppression.
Implementation Method 1
Aptamers are nucleic acid molecules having specific binding affinity to molecules through interactions other than classic Watson-Crick base pairing
Implementation Method 2
aptamers are capable of specifically binding to selected targets and modulating the target's activity, e.g., through binding aptamers may block their target's ability to function
Implementation Method 3
enhancing delivery of active agents to disease sites
Data Source
AI summary
Methods and compositions are provided for specific aptamers and aptamer pools that bind biomarkers of interest such as microvesicle surface antigens or functional fragments of microvesicle surface antigens. In various embodiments, aptamers of the invention are used in diagnostic, prognostic, or theranostic processes to screen a biological sample for the presence or levels of biomarkers such as microvesicles that are determined to provide a diagnostic, prognostic, or theranostic readout. The diagnosis, prognosis, or theranosis may be related to cancer or other diseases and disorders. The invention also provides methods and composition to facilitate aptamer library screening and aptamer detection methods.